Talk to Us

86849 prior authorization | Anthem Blue Cross Blue Shield of California

86849, Unlisted immunology procedure [when specified as in vitro chemosensitivity or in vitro chemoresistance assay, ex vivo analysis of programmed cell death] or [when specified as Complement Antigen Test for delayed food allergy, Mediator Release Test (MRT), or Basophil Activation Test (BAT) by flow cytometry], is on the Anthem Blue Cross Blue Shield of California PPO prior authorization list. Not a coverage or referral decision.

Code
86849
Description
Unlisted immunology procedure [when specified as in vitro chemosensitivity or in vitro chemoresistance assay, ex vivo analysis of programmed cell death] or [when specified as Complement Antigen Test for delayed food allergy, Mediator Release Test (MRT), or Basophil Activation Test (BAT) by flow cytometry]
Source
California PPO Prior Authorization List, Pg 13 Original policy

Anthem Blue Cross Blue Shield of California prior authorization

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.

This website uses cookies to ensure you get the best experience on our website. Learn more